Read by QxMD icon Read

Leukemia biomarker

Junsheng Ma, Francesco C Stingo, Brian P Hobbs
The evolution of "informatics" technologies has the potential to generate massive databases, but the extent to which personalized medicine may be effectuated depends on the extent to which these rich databases may be utilized to advance understanding of the disease molecular profiles and ultimately integrated for treatment selection, necessitating robust methodology for dimension reduction. Yet, statistical methods proposed to address challenges arising with the high-dimensionality of omics-type data predominately rely on linear models and emphasize associations deriving from prognostic biomarkers...
February 20, 2019: Biometrical Journal. Biometrische Zeitschrift
Amrita Soni, Chandra Mouli Pandey, Manoj Kumar Pandey, Gajjala Sumana
In this work, polyaniline nanospindles have been synthesized using iron oxide as sacrificial template. These nanospindles were utilized for the fabrication of PANI-MoS2 nanoflower architectures via hydrothermal route. The electrostatic interaction between PANI and MoS2 improves the conductivity and provides more direct paths for charge transportation. SEM, TEM, XRD, Raman Spectroscopy techniques were employed to explore the crystal structure, and morphological properties of the PANI-MoS2 nanocomposite. Furthermore, an electrochemical biosensing platform based on PANI-MoS2 nanocomposite was fabricated for the specific detection of chronic myelogenous leukemia (CML) by using electrochemical impedance spectroscopy technique...
May 9, 2019: Analytica Chimica Acta
Katarzyna Tomska, Sebastian Scheinost, Thorsten Zenz
Response to anticancer agents is often restricted to subsets of patients. The recognition of factors underlying this heterogeneity and the identification of biomarkers associated with response to drugs would greatly improve the efficacy of drug treatment. Platforms that can comprehensively map drug response in high-throughput ex vivo provide a unique tool to identify associated biomarkers and provide hypotheses for mechanisms underlying variable response. Such screens can be performed on cell lines and short-term cultures of primary cells to take advantage of the respective models' strength, which include, e...
2019: Methods in Molecular Biology
Vojin Vukovic, Teodora Karan-Djurasevic, Darko Antic, Natasa Tosic, Tatjana Kostic, Irena Marjanovic, Marija Dencic-Fekete, Vladislava Djurasinovic, Sonja Pavlovic, Biljana Mihaljevic
Fludarabine plus cyclophosphamide (FC) chemotherapy is the basis of treatment protocols used in management of chronic lymphocytic leukemia (CLL). In some patients, response to therapy may be affected by aberrant function of genes involved in pharmacokinetics and pharmacodynamics of the drugs. The aim of this research was to assess the impact of pharmacogenetic variability, namely expression of SLC28A3 gene and the presence of CYP2B6*6 variant allele, on the FC treatment efficacy. Forty-four CLL patients with functional TP53 gene at the time of FC initiation were enrolled in this study...
February 18, 2019: Pathology Oncology Research: POR
Habib Haybar, Saeid Shahrabi, Hadi Rezaeeyan, Hosein Jodat, Najmaldin Saki
OBJECTIVE: Arsenic trioxide (ATO) is a drug commonly used for the treatment of acute promyelocytic leukemia (APL). Although ATO has been shown to cause significant improvement in patients, it is associated with serious side effects, which sometimes lead to the patient's death. In this review paper, we examine the reports of ATO-induced cardiotoxicity in APL patients and evaluate the strategies to reduce the incidence of such toxicity. METHODS: The key search terms were "arsenic trioxide," "acute promyelocytic leukemia," "cardiotoxicity," "molecular pathway," and "biomarker...
February 15, 2019: Journal of Cellular Physiology
Fenglin Cao, Xingang Li, Yiju Yang, Honghong Fang, Haixia Qu, Naibai Chang, Qingwei Ma, Weifan Cao, Jin Zhou, Wei Wang
The introduction of arsenic trioxide (ATO) in treatment of acute promyelocytic leukemia (APL) has resulted in high clinical complete remission (CR) rates over 90%. On the contrary, the risk for early death (ED) in APL patients treated with ATO continues to have a negative impact for optimization of APL therapeutics. There is an urgent need for precision medicine and biomarkers in clinical monitoring of ATO toxicity in APL, and ED in particular. This retrospective case series cohort proteomics study was conducted as a hypothesis generation effort and provides here several potential molecular leads on serum peptides expressed at different times after treatment with ATO in patients with APL...
February 2019: Omics: a Journal of Integrative Biology
Lei Ping, Chen Jian-Jun, Liao Chu-Shu, Liu Guang-Hua, Zhou Ming
Chronic myeloid leukemia (CML) is a rare clonal myeloproliferative malignancy, which is caused by a reciprocal translocation between chromosomes 9 and 22 t(9;22) (q34;q11). Altered circle RNAs (circRNAs) could contribute to leukemogenesis. In this study, we aimed to investigate the expression profiling of circRNAs in CML. We performed circRNA-sequencing to identify differentially expressed circRNAs in CML cells. Furthermore, we found that circ_100053 was significantly upregulated in peripheral blood mononuclear cells (PBMC) and serum samples from CML compared with healthy controls...
February 14, 2019: Oncology Research
Yair Herishanu, Tamar Tadmor, Andrei Braester, Osnat Bairey, Ariel Aviv, Naomi Rahimi-Levene, Riva Fineman, Itai Levi, Mona Yuklea, Rosa Ruchlemer, Lev Shvidel, Aaron Polliack
Chronic lymphocytic leukemia (CLL) is a disease of elderly patients. The fludarabine, cyclophosphamide and rituximab (FCR) regimen is considered the treatment of choice for young fit patients with CLL, however, this combination is toxic for older patients. At the time this study was first planned and initiated, there was no standard chemo-immunotherapy regimen regarded as standard therapy for the less fit elderly patient with CLL. Here we conducted a single arm, phase II trial to examine the efficacy and safety of lower-dose fludarabine and cyclophosphamide combined with a standard dose of rituximab (LD-FCR) in elderly patients with previously untreated CLL...
February 12, 2019: Hematological Oncology
Gabriela Marisol Cruz-Miranda, Alfredo Hidalgo-Miranda, Diego Alberto Bárcenas-López, Juan Carlos Núñez-Enríquez, Julian Ramírez-Bello, Juan Manuel Mejía-Aranguré, Silvia Jiménez-Morales
Acute leukemia (AL) is the main type of cancer in children worldwide. Mortality by this disease is high in developing countries and its etiology remains unanswered. Evidences showing the role of the long non-coding RNAs (lncRNAs) in the pathophysiology of hematological malignancies have increased drastically in the last decade. In addition to the contribution of these lncRNAs in leukemogenesis, recent studies have suggested that lncRNAs could be used as biomarkers in the diagnosis, prognosis, and therapeutic response in leukemia patients...
February 9, 2019: International Journal of Molecular Sciences
Chadarat Ampasavate, Wasimon Jutapakdee, Rungsinee Phongpradist, Singkome Tima, Adisak Tantiworawit, Pimlak Charoenkwan, Dujrudee Chinwong, Songyot Anuchapreeda
BACKGROUND: Overexpression of fms-like tyrosine kinase 3 (FLT3) protein in leukemia is highly related to poor prognosis and reduced survival rate in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients. Simple but efficient quantification of FLT3 protein levels on the leukemic cell surface using flow cytometry had been developed for rapid determination of FLT3 on intact cell surface. METHODS: Quantitation protocol for FLT3 biomarker in clinical samples was developed and validated...
February 8, 2019: Journal of Clinical Laboratory Analysis
Kate J Johnstone, Geoffrey M Strutton
BRAF mutation status is a critical predictive and prognostic biomarker in guiding management of unresectable and metastatic melanoma.1 We recently observed a case of BRAF V600E-mutated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) intermixed with BRAF V600E wild-type melanoma reported to harbor BRAF V600E mutation on molecular testing. Our observation underscores the importance of appropriate tumor selection for molecular studies and knowledge of mutational status of co-existing tumors. This article is protected by copyright...
February 7, 2019: Journal of Cutaneous Pathology
Kodappully S Siveen, Kirti S Prabhu, Aeijaz S Parray, Maysaloun Merhi, Abdelilah Arredouani, Mohamed Chikri, Shahab Uddin, Said Dermime, Ramzi M Mohammad, Martin Steinhoff, Ibrahim A Janahi, Fouad Azizi
Patients treated during leukemia face the risk of complications including pulmonary dysfunction that may result from infiltration of leukemic blast cells (LBCs) into lung parenchyma and interstitium. In LBCs, we demonstrated that transient receptor potential vanilloid type 2 channel (TRPV2), reputed for its role in inflammatory processes, exhibited oncogenic activity associated with alteration of its molecular expression profile. TRPV2 was overexpressed in LBCs compared to normal human peripheral blood mononuclear cells (PBMCs)...
February 7, 2019: Scientific Reports
Kanchun Dai, Qianying Zhang, Yingying Li, Luyi Wu, Shenghui Zhang, Kang Yu
To assess plasma fibrinogen levels as a biomarker to predict the prognosis and treatment outcome in acute myeloid leukemia (AML), a retrospective study of 215 patients with AML excluding M3 was conducted in a single center. Patients were divided into low and high group according to the cutoff value of 3.775 g/L obtained by analyzing the receiver operating characteristic (ROC) curve of fibrinogen at diagnosis. Importantly, overall survival (OS) was markedly better in low fibrinogen group (p=.006) as well as disease-free survival (DFS) (p= ...
February 8, 2019: Leukemia & Lymphoma
Diana Raluca Maniu, Cristina Blag, Gheorghe Popa, Madalina Bota, Catalin Vlad, Calin Cainap, Ovidiu Balacescu, Laura Pop, Simona Sorana Cainap
PURPOSE: To describe the high-risk profile group, susceptible to develop anthracycline-induced cardiomyopathy in children with acute leukemia. METHODS: The study involved 35 pediatric patients diagnosed with acute lymphoblastic (ALL) or acute myeloblastic leukemia (AML), from March 2014 to December 2016. Serologic markers used for the analysis of cardiac dysfunction were troponin T, NT-proBNP and PCRhs. Also, the patients have had echocardiographic evaluation at the beginning of treatment to determine LVEF, SF and A, E, E' Doppler waves...
December 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
Cheng-Cao Sun, Shu-Jun Li, Zhen-Long Chen, Guang Li, Qian Zhang, De-Jia Li
Despite advances in early diagnosis and treatment, cancer remains the major reason for mortality worldwide. The Runt-related transcription factor (RUNX) family has been reported to participate in diverse human diseases. However, little is known about their expression and prognostic values in human leukemia. Herein, we conducted a detailed cancer versus normal analysis. The mRNA expression levels of the RUNX family in various kinds of cancers, including leukemia, were analyzed via the ONCOMINE and GEPIA (Gene Expression Profiling Interactive Analysis) databases...
March 29, 2019: Molecular Therapy Oncolytics
Bei Jia, Chenchen Zhao, Kevin L Rakszawski, David F Claxton, W Christopher Ehmann, Witold B Rybka, Shin Mineishi, Ming Wang, Hiroko Shike, Michael G Bayerl, Jeffrey M Sivik, Todd D Schell, Joseph J Drabick, Raymond J Hohl, Hong Zheng
Acute myeloid leukemia (AML) is a devastating blood cancer with poor prognosis. Immunotherapy targeting inhibitory pathways to unleash the anti-leukemia T cell response is a promising strategy for the treatment of leukemia, but we must first understand the underlying molecular mechanisms. Eomesodermin (Eomes) and T-bet are both T-box transcription factors that regulate CD8+ T cell responses in a context-specific manner. Here we examined the role of these transcription factors in CD8+ T cell immunity in AML patients...
February 1, 2019: Cancer Research
Yao Xue, Yuqiu Ge, Meiyun Kang, Cong Wu, Yaping Wang, Liucheng Rong, Yongjun Fang
BACKGROUND: MiRNAs that are potential biomarkers for predicting prognosis for acute myeloid leukemia (AML) have been identified. However, comprehensive analyses investigating the association between miRNA expression profiles and AML survival remain relatively deficient. METHOD: In the present study, we performed multivariate Cox's analysis and principal component analysis (PCA) using data from The Cancer Genome Atlas (TCGA) to identify potential molecular signatures for predicting non-M3 AML prognosis...
January 30, 2019: BMC Cancer
Dong Wang, Guangguo Tan, Haibo Wang, Peng Chen, Jie Hao, Yanyu Wang
Acute myeloid leukemia (AML) is a life-threatening hematological malignancy. Traditional diagnosis of AML depends on invasive bone marrow biopsies. To recognize the metabolic characteristics related with AML and search for early non-invasive biomarkers of AML, in this work we applied ultra-high performance liquid chromatography quadrupole time-of-flight tandem mass spectrometry (UHPLC-Q-TOFMS)-based metabolomoc method to profile serum metabolites from 55 de novo AML patients and 45 age- and gender-matched healthy subjects and to screen and validate AML biomarkers...
January 14, 2019: Journal of Pharmaceutical and Biomedical Analysis
Adalgisa Condoluci, Davide Rossi
Several recurrently deregulated pathways implicated in the development of chronic lymphocytic leukemia (CLL) have been described over the last decades. Knowledge of the CLL genetic heterogeneity led to the definition of molecular biomarkers informing about prognosis and treatment outcome. Areas covered: English literature published from January 2008 through December 2018 was searched in PubMed, Cochrane Central Register of Controlled Trials, and hematology meeting abstracts to obtain literature on clinical predictive factors for CLL...
January 28, 2019: Expert Review of Hematology
Jian-Cang Wang, Fei-Fan Du, Ming Su, Xiao-Ge Yang, Mei-Jie Quan, Xiao-Ying Zhai
No abstract text is available yet for this article.
February 5, 2019: Chinese Medical Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"